Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Fulminant hepatic failure associated with bicalutamide

L A Dawson1, E Chow, G Morton

  • 1Department of Radiation Oncology, Toronto-Sunnybrook Regional Cancer Centre, University of Toronto, Ontario, Canada.

Urology
|February 1, 1997
PubMed
Summary

Bicalutamide, a nonsteroidal antiandrogen, is generally well-tolerated. However, this report details the first known case of severe liver injury, or fulminant hepatic failure, linked to its use.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The role of stereotactic body radiotherapy in the management of hepatocellular carcinoma with macroscopic vascular invasion: a narrative review.

ESMO gastrointestinal oncology·2026
Same author

A randomized Phase II trial of High Dose-Rate (HDR) and Low Dose-Rate (LDR) brachytherapy as monotherapy in localized prostate cancer: analysis of initial arms of Canadian cancer trials group PR19 (NCT02960087).

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2025
Same author

Tumour-Specific Growth Rate as a Potential Predictor of Outcomes in Oligoprogressive Disease Treated With Stereotactic Body Radiotherapy.

Clinical oncology (Royal College of Radiologists (Great Britain))·2025
Same author

Hepatocellular carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

The maximum dose of atorvastatin and simvastatin as well as rosuvastatin should be restricted in East Asians.

Hong Kong medical journal = Xianggang yi xue za zhi·2024
Same author

Brachytherapy for high grade prostate cancer induces distinct changes in circulating CD4 and CD8 T cells - Implications for systemic control.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2024

Area of Science:

  • Hepatology
  • Pharmacology
  • Oncology

Background:

  • Bicalutamide is a widely prescribed nonsteroidal antiandrogen medication.
  • It is commonly used in the treatment of prostate cancer.
  • The drug is known for its generally favorable toxicity profile.

Observation:

  • This case report describes a patient who developed severe liver complications.
  • The patient experienced fulminant hepatic failure, a rare but life-threatening condition.
  • This adverse event occurred during bicalutamide therapy.

Findings:

  • This is the first documented instance of fulminant hepatic failure attributed to bicalutamide.
  • The findings highlight a potential, albeit rare, severe adverse effect of the drug.

Related Experiment Videos

  • Further investigation into the mechanisms of bicalutamide-induced hepatotoxicity may be warranted.

    • Implications:

    • Clinicians should be aware of the potential for severe liver injury with bicalutamide use.
    • Early recognition and prompt management are crucial for patients experiencing hepatic adverse events.
    • This case underscores the importance of post-marketing surveillance for drug safety.